but Saxenda is a higher dose. Although the target for each formulation is the same (the GLP-1 receptor), for glucose control in type 2 diabetes, liraglutide has to (mainly) reach the pancreas.

In the new SCALE Kids study, which has been published in the New England Journal of Medicine, a daily 3mg dose of Saxenda reduced the body mass index (BMI) of the children by an average of 5.8% ...